Altamira Therapeutics Net Income vs. Current Ratio
| CYTO Stock | USD 0.42 0.01 2.33% |
Net Loss | First Reported 2013-03-31 | Previous Quarter -2.7 M | Current Value -2.7 M | Quarterly Volatility 2.9 M |
For Altamira Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Altamira Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Altamira Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Altamira Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Altamira Therapeutics over time as well as its relative position and ranking within its peers.
Altamira |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Altamira Therapeutics Current Ratio vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Altamira Therapeutics's current stock value. Our valuation model uses many indicators to compare Altamira Therapeutics value to that of its competitors to determine the firm's financial worth. Altamira Therapeutics is rated second in net income category among its peers. It is rated below average in current ratio category among its peers . Altamira Therapeutics reported last year Net Loss of (7.27 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Altamira Therapeutics' earnings, one of the primary drivers of an investment's value.Altamira Current Ratio vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Altamira Therapeutics |
| = | (3.87 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Altamira Therapeutics |
| = | 0.77 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Altamira Current Ratio Comparison
Altamira Therapeutics is currently under evaluation in current ratio category among its peers.
Altamira Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Altamira Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Altamira Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Altamira Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Altamira Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 177.6 K | 186.5 K | |
| Operating Income | -5.9 M | -6.2 M | |
| Income Before Tax | -7.3 M | -7.6 M | |
| Total Other Income Expense Net | -1.4 M | -1.3 M | |
| Net Loss | -3.9 M | -4.1 M | |
| Income Tax Expense | -1.4 M | -1.3 M | |
| Net Interest Income | -730.2 K | -766.7 K | |
| Interest Income | 302.2 K | 317.4 K | |
| Net Loss | -7.3 M | -7.6 M | |
| Net Loss | -20 M | -21 M | |
| Change To Netincome | 3.6 M | 3.8 M | |
| Net Loss | (14.81) | (15.55) | |
| Income Quality | 2.98 | 3.12 | |
| Net Income Per E B T | 1.15 | 1.10 |
Altamira Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Altamira Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Altamira Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Altamira Therapeutics' important profitability drivers and their relationship over time.
Use Altamira Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altamira Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altamira Therapeutics will appreciate offsetting losses from the drop in the long position's value.Altamira Therapeutics Pair Trading
Altamira Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Altamira Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altamira Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altamira Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altamira Therapeutics to buy it.
The correlation of Altamira Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altamira Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altamira Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altamira Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Altamira Therapeutics position
In addition to having Altamira Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Altamira Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Altamira Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Altamira Therapeutics' income statement, its balance sheet, and the statement of cash flows.